Santhera Completes Enrollment of Phase 3 SIDEROS Study with Puldysa® (Idebenone) in Duchenne Muscular Dystrophy (DMD)

Print Friendly, PDF & Email

RE: DUCHENNE MUSCULAR DYSTROPHY (DMD): Pratteln, Switzerland, May 20, 2020 – Santhera Pharmaceuticals (SIX: SANN) announces full recruitment of its Phase 3 SIDEROS study with idebenone in Duchenne muscular dystrophy (DMD). The sample-size and variability re-assessment performed according to study protocol demonstrated that with the currently enrolled patients the study has a very high […]